Last reviewed · How we verify
Pathogen reduction process
A pathogen reduction technology that inactivates viruses, bacteria, and other pathogens in blood products through chemical or physical treatment to improve transfusion safety.
A pathogen reduction process inactivates viruses, bacteria, and other pathogens in blood products through physical or chemical treatment to improve transfusion safety. Used for Reduction of transfusion-transmitted viral infections in plasma, Reduction of transfusion-transmitted viral and bacterial infections in platelet concentrates, Reduction of transfusion-transmitted infections in red blood cell products.
At a glance
| Generic name | Pathogen reduction process |
|---|---|
| Sponsor | Etablissement Français du Sang |
| Drug class | Blood product safety technology |
| Modality | Biologic |
| Therapeutic area | Hematology / Transfusion Medicine |
| Phase | FDA-approved |
Mechanism of action
Pathogen reduction processes use methods such as photochemical treatment (e.g., with psoralens and UV light) or other inactivation techniques to neutralize a broad spectrum of pathogens including enveloped and non-enveloped viruses, bacteria, and parasites in blood components. This reduces the risk of transfusion-transmitted infections while maintaining the hemostatic function of the treated blood product.
Approved indications
- Pathogen reduction of blood components (red blood cells, platelets, plasma) for transfusion
Common side effects
- Reduced platelet viability or function
- Hemolysis in treated red blood cells
- Coagulation factor reduction in treated plasma
Key clinical trials
- INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (PHASE3)
- Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (PHASE3)
- Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs (PHASE2)
- Effect of a 'Rapid-Return-to-work Program' in Mild Mental Disorders. (NA)
- INTERCEPT Safety Evaluation in Anemic Patients (NA)
- Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (PHASE4)
- Italian Platelet Technology Assessment Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pathogen reduction process CI brief — competitive landscape report
- Pathogen reduction process updates RSS · CI watch RSS
- Etablissement Français du Sang portfolio CI